AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

Courtesy of Smith Collection/Gado/Getty Images

Drug Development

AbbVie Receives NDA for Atogepant, Aims to Stop Migraines in Their Tracks

AbbVie won the NDA on the strength of definitive results in a Phase III ADVANCE trial, where atogepant met all six secondary endpoints at the 30-60 mg dose range, proving statistically significant in heading off migraines in nearly 2500 adult participants who experience them between 4-14 days per month.

March 30, 2021

2 min read

Heather McKenzie

SKYRIZI is the new option for psoriatic arthritis.

Policy

AbbVie Legal Complaint Alleges Alvotech Misappropriated Humira Trade Secrets

AbbVie has filed a legal complaint against Icelandic pharmaceutical company Alvotech for the latter’s alleged misappropriation of trade secrets involving the development of a generic version of AbbVie’s rheumatoid arthritis drug Humira.

March 24, 2021

3 min read

Brandon May

Drug Development

ICYMI: A Closer Look at News You Might Have Missed This Week

The results published in the NEJM state that pegcetacoplan met the study’s primary endpoint for efficacy, demonstrating an advantage over eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p<0.001). An impressive 85% of patients were transfusion free at 16 weeks, in contrast to only 15% of eculizumab-treated patients.

March 18, 2021

7 min read

Heather McKenzie

BioMidwest

AbbVie Could Sell Off $5 Billion Portfolio of Women’s Drugs

One year after AbbVie’s $63 billion purchase of Allergan, the company is reportedly lining up the sale of a portfolio of women’s drugs and health care products valued at $5 billion.

March 16, 2021

2 min read

Alex Keown

BioMidwest

AbbVie to Fund Mitokinin’s Parkinson Research with Option to Buy

AbbVie bought an exclusive right to acquire San Francisco-based Mitokinin after the company completes its Investigational New Drug-enabling studies on its lead program, PINK1, for Parkinson’s disease.

March 2, 2021

2 min read

Mark Terry

Deals

Beijing CRMO Further Expands UK Footprint with Abbvie’s Allergan Site

Beijing-based CRMO Pharmaron has accomplished impressive global growth via acquisitions over the past eight months.

March 1, 2021

2 min read

Kate Goodwin

AbbVie_© AbbVie Inc. All rights reserved.

FDA

Humira Bags Another FDA Approval, This Time for Pediatric Ulcerative Colitis

The U.S. Food and Drug Administration has approved AbbVie’s biologic therapy HUMIRA® (adalimumab) as a treatment for moderate-to-severe active ulcerative colitis in children aged 5 years and older.

February 25, 2021

2 min read

Brandon May

Policy

AbbVie Settles Botox Rival IP Lawsuit with Evolus

AbbVie and its partner company, Medytox of South Korea, have settled a years-long intellectual property legal dispute with California’s Evolus over Jeuveau, a potential rival to AbbVie’s blockbuster Botox, which it gained through the acquisition of Allergan.

February 19, 2021

2 min read

Alex Keown